现代医学研究发现,通络药物可以全面阻击心脑血管病的发生。过去,由于受到传统制药工艺的制约,通络药物的有效成分不能充分释放,药效不能充分发挥,为此,以岭药业与清华大学合作,历经五年的时间,将超微粉技术应用于通络的代表药物—— Modern medical research found that Tongluo drugs can completely block the occurrence of cardiovascular and cerebrovascular diseases. In the past, due to the constraints of traditional pharmaceutical processes, the active ingredients of Tongluo Pharmaceuticals could not be fully released and the efficacy could not be fully utilized. Therefore, after cooperation between Lingye Pharmaceutical and Tsinghua University, ultrafine powder technology was applied for five years. Tongluo’s representative drug -